Adial Pharmaceuticals (NASDAQ:ADIL) stock is heading higher on Wednesday following positive results from a peer review of its Alcohol Use Disorder (AUD) treatment. This peer review focuses on Phase 3 clinical trial results for AD04. The article highlights the positive performance of the treatment as well as the safety data. The publication behind this article is the European Journal of Internal Medicine. Adial Pharmaceuticals CEO Cary Claiborne said the following about the peer-reviewed results. “Most impor ...